Two years af­ter flop, Verona gets a win as it preps for piv­otal Phase III tri­als

Two years af­ter the lead for­mu­la­tion of Verona’s lead COPD drug whiffed in a Phase II study that knocked back their stock, an­oth­er for­mu­la­tion has hit across the board.

Verona said Tues­day that all four dos­es of an in­haler form of its com­pound en­sifen­trine sig­nif­i­cant­ly im­proved lung func­tion in a 40-per­son Phase II tri­al of the chron­ic con­di­tion. Most dos­es of the drug hit on all pri­ma­ry and sec­ondary end­points, with the ef­fect in­creas­ing with the dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER